These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33871726)

  • 1. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
    Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
    Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-based contrast agents: A comprehensive risk assessment.
    Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
    J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
    Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
    Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
    Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
    Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of gadolinium-based contrast agents (GBCAs)-adverse reactions.
    Boehm IB
    Magn Reson Imaging; 2022 Jan; 85():1-2. PubMed ID: 34662698
    [No Abstract]   [Full Text] [Related]  

  • 9. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG
    Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
    Holowka S; Shroff M; Chavhan GB
    Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
    Bäuerle T; Saake M; Uder M
    Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
    McDonald JS; McDonald RJ
    Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 18. Gadolinium contrast agents - are they really safe?
    Malikova H; Holesta M
    J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
    Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
    AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.